Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM VACCINE

3.260
+0.0401.24%
Volume:683.60K
Turnover:2.21M
Market Cap:4.00B
PE:-13.34
High:3.270
Open:3.240
Low:3.200
Close:3.220
Loading ...

AIM Vaccine Co Ltd - Placing of 15.5 Mln Shares at HK$5.01 per Share

THOMSON REUTERS
·
28 Feb

BUZZ-China's AIM jumps on approval of vaccine's clinical trial in US

Reuters
·
27 Feb

AIM Vaccine Gets US FDA Clinical Trial Nod for Respiratory Syncytial Virus Jab

MT Newswires Live
·
27 Feb

BRIEF-AIM Vaccine Says Clinical Trial Of MRNA Respiratory Syncytial Virus Vaccines Approved By FDA

Reuters
·
26 Feb

AIM Vaccine Co Ltd - Clinical Trial of Mrna Respiratory Syncytial- Virus Vaccines Approved by FDA

THOMSON REUTERS
·
26 Feb

AIM Vaccine Submits US Clinical Trial Application for Shingles Jab

MT Newswires Live
·
24 Feb

BRIEF-AIM Vaccine Says Fully Integrates Deepseek In All Business Scenarios

Reuters
·
23 Feb

AIM Vaccine Says Co Fully Integrates Deepseek in All Business Scenarios, Covering R&D, Production, Sales

THOMSON REUTERS
·
23 Feb

AIM Vaccine Submits Clinical Trial Application for mRNA Shingles Vaccine to Chinese Regulator

MT Newswires Live
·
12 Feb

AIM Vaccine Mrna Rsv Vaccine Submits for Clinical Trials in the U.S.

THOMSON REUTERS
·
06 Feb

AIM Submits Clinical Trial Application to US FDA for mRNA RSV Vaccine

MT Newswires Live
·
05 Feb

BUZZ-China's AIM jumps on vaccine's clinical trial application in US

Reuters
·
05 Feb

AIM Vaccine For Tetanus Gets NMPA's Nod; Shares Rise 5%

MT Newswires Live
·
20 Dec 2024

AIM Vaccine Has Obtained Clinical Approval for Two Heavyweight Products, Creating New Growth Points for Performance

THOMSON REUTERS
·
20 Dec 2024

BRIEF-AIM Vaccine Says Second Generation Of Absorbed Tetanus Vaccine Obtained Clinical Trial Approval

Reuters
·
19 Dec 2024

BRIEF-AIM Vaccine Says Suspension Culture Influenza Vaccine (MDCK Cells) Got Clinical Trial Approval

Reuters
·
19 Dec 2024

AIM Vaccine - Second Generation of Highly-Effective Absorbed Tetanus Vaccine Obtained Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
19 Dec 2024

AIM Vaccine Co - Suspension Culture Influenza Vaccine (Mdck Cells) Got Clinical Trial Approval From China's Nmpa

THOMSON REUTERS
·
19 Dec 2024

the Global Leader in Rabies Vaccines, the Serum-Free Iterative Rabies Vaccine of AIM Vaccine Has Submitted a Pre-Application for Marketing Registration

THOMSON REUTERS
·
18 Nov 2024

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Simply Wall St.
·
15 Nov 2024